Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 440.40
Bid: 439.80
Ask: 440.60
Change: -9.00 (-2.00%)
Spread: 0.80 (0.182%)
Open: 450.60
High: 450.60
Low: 436.80
Prev. Close: 449.40
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

30 Sep 2015 07:00

RNS Number : 6226A
QinetiQ Group plc
30 September 2015
 

 

News release

QinetiQ Group plc

 

Pre Close Trading Update

 

Ahead of QinetiQ entering its closed period for the half year ending 30 September 2015, we will be holding our customary pre-close meetings with analysts today. No new material information will be disclosed in these meetings.

The Board is maintaining its expectations for Group performance this financial year.

In the UK, the Government's Strategic Defence and Security Review (SDSR), and public consultation on the proposed approach to calculating the baseline profit rate for single source contracts, are both underway.

The EMEA Services division continues to see some customer contract award decisions deferred due to uncertainties in the UK market or delayed by requirements for additional approvals. However, revenue under contract for this financial year is as expected at this stage.

As anticipated, the Group's Global Products division continues to trade at similar levels to the prior year.

QinetiQ's interim results for the half year ending 30 September 2015 will be announced on 19 November 2015.

ENDS

 

Notes to Editors:

A FTSE250 company, QinetiQ uses its world class knowledge, research and innovation to provide high-end technical expertise and advice, to customers in the global aerospace, defence and security markets. QinetiQ's unique position enables it to be a trusted partner to government organisations, predominantly in the UK and the US, including defence departments as well as other international customers in targeted sectors. For more information see www.QinetiQ.com.

For further information please contact:

Investor relations:

David Bishop, QinetiQ

+44 (0) 7920 108675

Media relations:

QinetiQ press office

+44 (0) 1252 393500

Rebecca Mitchell, Maitland

+44 (0) 207 379 5151

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFVRATIAFIE
Date   Source Headline
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20241:54 pmRNSDirector Declaration
5th Mar 202412:08 pmRNSDirector Declaration
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20244:00 pmRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.